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Abstract
Given that the transcriptional regulatory activity of estrogen receptor (ER) is modulated by its biochemical cofactors, genetic
variation within the ER cofactor genes may alter cellular response to estrogen exposure and consequently modify the risk
for endometrial cancer. We genotyped 685 tagging SNPs within 60 ER cofactor genes in 564 endometrial cancer cases and
1,510 controls from Sweden, and tested their associations with the risk of endometrial cancer. We investigated the
associations of individual SNPs by using a trend test as well as multiple SNPs within a gene or gene complex by using multi-
variant association analysis. No significant association was observed for any individual SNPs or genes, but a marginal
association of the cumulative genetic variation of the NCOA2 complex as a whole (NCOA2, CARM1, CREBBP, PRMT1 and
EP300) with endometrial cancer risk was observed (Padjusted = 0.033). However, the association failed to be replicated in an
independent European dataset of 1265 cases and 5190 controls (P = 0.71). The results indicate that common genetic variants
within ER cofactor genes are unlikely to play a significant role in endometrial cancer risk in European population.
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Introduction
Endometrial cancer is the most common gynecological cancer
in Western countries and its incidence is increasing [1]. Biological,
clinical and epidemiological studies have demonstrated that
unopposed estrogen stimulates cell proliferation and induces
carcinoma development of endometrial cancer [2,3]. Estrogen
plays its role in endometrial cancer development via the estrogen
receptor by promoting its dimerization and translocation to the
nucleus, where it modulates the expression of estrogen responsive
genes [4].
Efficient transcription regulation by the estrogen receptor
requires the participation of a class of proteins known as nuclear
receptor coregulators, which consist of coactivators and corepres-
sors [5,6]. These coregulators play an important role in a variety of
human diseases, including cancer and some metabolic disorders
[7]. Nuclear receptor coactivators are rate-limiting in steroid
receptor-mediated gene transcription [8–10] and have the ability
to reverse the squelching of the transcriptional activity of one
steroid receptor by another [9]. In addition to functioning as
a bridge between receptors and the general transcriptional
machinery, nuclear receptor coactivators act as cofactor com-
plexes influencing receptor transcription regulation through
a variety of mechanisms, including phosphorylation, acetylation,
methylation, RNA splicing and chromatin remodeling [10,11].
One family of coactivators, the P160 family is well-known to
bind directly to hormone-activated estrogen receptors and recruit
secondary coactivators [12,13], where the CREBBP and the
CARM1 form an interaction domain that physically overlaps with
the related transferable activation domains of the p160 family
members [14]. Moreover, it is reported that a ternary complex
formed by NCOA2, CARM1 and EP300 or CREBBP could enhance
estrogen receptor (ER) function in an augmentation manner [15].
While the common genetic variation within hormone-related
genes [16,17] and the estrogen metabolism pathway [18] have
been shown to be associated with endometrial cancer risk, the
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genetic variation of the ER cofactor genes, to our knowledge, has
not carefully been examined for their involvement in the
development of endometrial cancer.
In the current paper, we aimed to carry out a comprehensive
association study of the polymorphisms within the ER cofactor
genes with endometrial cancer risk. We conducted the discovery
study in a population-based endometrial cancer sample of
postmenopausal Swedish women and performed a validation
analysis in an independent European dataset.
Results
Discovery Analysis
A total of 564 cases and 1510 controls were included in the
discovery analysis (Table 1). All of the cases and controls were
postmenopausal Swedish women. We successfully genotyped 685
tag SNPs within the 60 ER cofactor genes, which can capture
2410 common SNPs (MAF.5%) with 91% coverage in average
(r2.0.8) according to the HapMap database. Out of these, 51
genes had coverage over 80%. Details of the SNP coverage
evaluation is summarized in Table S1. In addition, we re-
evaluated the coverage of same set of tag SNPs on variants
MAF.5% in the 1000 genomes project database, which is an
updated and more comprehensive catalog of human genome
variation. The average coverage decreased to 64% and 19 genes
had coverage over 80%. However, with r2.0.8, 5084 SNPs had
been captured among 7141 SNPs in the 60 genes.
Of the 685 tag SNPs analyzed, nominal P values of less than
0.05 were found for 42 SNPs (6.13%). The Q-Q plot of the
observed p-values from the association tests is shown in Figure 1,
in which genomic control inflation factor is 1.058, with no clear
evidence of deviation from the null. The most significant
association was observed at SNP rs130052 (MAF =0.13) within
the CREBBP gene (odds ratio (OR) = 1.41 (95% CI 1.16–1.72),
age-adjusted P= 0.002). The ORs with or without age-adjustment
were similar. No P-values of individual SNPs could, however,
survive the Bonferroni correction for multiple testing.
We further evaluated the association of the genetic variants
within each individual ER cofactor gene by carrying out multiple
variant association analysis through the Admixture Maximum
Likelihood (AML) test, to provide a gene-based P value (Table S3).
We found the associations of four genes, CREBBP (P = 0.017),
NEDD4 (P = 0.030), NCOA2 (P = 0.037) and NR0B1 (P = 0.031)
with nominal P values ,0.05 (Table 2). However, after correction
for multiple testing, none of the associations remained significantly
associated with endometrial cancer risk.
In view of ER cofactor genes playing their roles via protein
complexes, we investigated the associations of the five ER cofactor
complexes using AML, namely the P160 family related histone
acetylation & methylation complexes (containing CARM1,
PRMT1, CREBBP, EP300, NCOA1, NCOA2 and NCOA3); the
RNA processing complex (PPARGC1A, PPARGC1B and SRA); the
Pol II recruitment complex (MED13 and PBP); the ligand-
dependent corepressors (NRIP1 and LCoR) and the histone
deacetylases complex (HDAC7 and NCoR1). Among the five
complexes, the P160 family related histone acetylation and
methylation complex showed association (Poverall = 0.023), but
the association could not survive the correction for testing five
independent complex groups (Poverall = 0.115) (Table 3).
As the three individual P160 histone acetylation & methylation
complexes (NCOA1, NCOA2 and NCOA3) play a distinct role in the
transcriptional regulation, we further investigated the associations
of these sub-complexes using the AML test. While the NCOA1 and
NCOA3 sub-complexes did not show association, the NCOA2 sub-
complex demonstrated a significant association (Poverall = 0.011)
Table 1. Endometrial cancer sample sets and sources included in initial and validation analysis.
Study Source Cases Controls Genotyping platform
Discovery analysis
Swedish Endometrial Cancer StudyPopulation based case-control study in
Swedish postmenopausal women




Population based case-control study in
Australia
599 Illumina 610 K
Study of Epidemiology and Risk
Factors in Cancer Heredity
Population based case-control study in
England
666 Illumina 610 K
Wellcome Trust Case-Control
Consortium
Sample from 1958 Birth Cohort and UK
Blood Donors from NBS
5190 Illumina 1.2 M
doi:10.1371/journal.pone.0042445.t001
Figure 1. QQ plot for trend tests of 685 ER cofactor SNPs
associated with endometrial cancer risk in the Swedish
population.
doi:10.1371/journal.pone.0042445.g001
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(Table 4), which remained significant after correction for testing
three sub-complexes (Poverall = 0.033).
Validation Analysis Using an in Silico Replication Set
Although the cumulative genetic variants in the P160 family
complex were not significant after multiple adjustments, the
further sub-complex analysis may indicate the source of signal
located on NCOA2 sub-complex. Therefore, we attempted to
validate the result in an independent European dataset of 1265
endometrial cancer cases and 5190 controls for which GWAS
genotyping data exists [19]. We extracted SNPs from the Illumina
Infinium 610K array panel located within 5 kb flanking the five
genes of the sub-complex. In total, 65 SNPs were identified and 53
SNPs passed quality control (Table S4). The coverage of common
SNPs was 96% in the NCOA2, 86% in the CREBBP, 80% in the
CARM1, 50% in the EP300 and 20% in the PRMT1 (Table S5).
The AML test was applied on each of the five genes and the whole
sub-complex (Table 5), but none of them showed significant
association (P= 0.71 for the sub-complex).
The sufficient genotyped SNPs and high coverage allowed us to
perform imputation analysis on the two genes, NCOA2 and
CREBBP in both the Swedish and the European samples. A total
of 19 SNPs on CREBBP and 270 SNPs on NCOA2 were shared
between the two datasets. We performed meta-analysis of the
results for these SNPs across the two datasets. However, no SNP
was found to be significantly associated with the risk of
endometrial cancer (Table 6 and Table S6).
Discussion
To our knowledge, this is the first comprehensive analysis of the
association between the polymorphisms of ER cofactor genes and
endometrial cancer risk. We did not find significant association
between single SNPs or individual genes associated with endome-
trial cancer risk. Although the genetic variation of the NCOA2
complex as a whole is marginally associated with endometrial
cancer risk in the Swedish population, we failed to validate this
finding in an independent study of subjects of European ancestry.
Perissi and Rosenfeld [13] described a vast number of
coregulator-complexes that are engaged in ER mediated tran-
Table 2. Top four most significant genes associated with endometrial cancer risk in the Swedish population.
Function Gene(alias) Chr SNP# P-value+ Most significant SNP ID
Most significant SNP’s P-
value
Coactivator CREBBP 16 18 0.017 rs130052 0.00046
Coactivator NEDD4 15 34 0.03 rs8033275 0.0066
Coactivator NCOA2 8 27 0.037 rs10216778 0.0051
Corepressor NROB1 X 9 0.031 rs1034948 0.012
+P value is based on 5000 permutations in AML test for the specific gene.
doi:10.1371/journal.pone.0042445.t002
Table 3. Global P values of AML tests for genetic association
between the tag SNPs in the ER cofactor complexes and
endometrial cancer risk in the Swedish population.










RNA processing PPARGC1A 46 0.674
PPARGC1B 41
SRA1 5






Histone deacetylase HDAC7 10 0.576
NCoR1 3
P-values were based on 5000 permutations.
doi:10.1371/journal.pone.0042445.t003
Table 4. Sub-complex AML tests for genetic association
between the tag SNPs in the histone acetylation &
methylation and endometrial cancer risk in the Swedish
population.
Sub-complex Gene #tagSNPs Pglobal
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scriptional regulation with various functions and enzymatic
activities. A study conducted by Lee and colleagues demonstrated
that NCOA2, CARM1 and EP300 or CREBBP form a ternary
complex that could enhance estrogen receptor (ER) function in
a synergistic manner [15]. Although the discovery analysis in our
study demonstrated with marginal significance that the cumulative
effects of multiple variants of NCOA2 complex may have
a contribution to the risk of endometrial cancer, the association
failed to be replicated in an independent sample.
It has been reported [20,21] that ER coactivators are more
commonly expressed in ER-positive endometrial cancer or well-
differentiated, hormone-related endometrial cancer rather than
ER-negative endometrial cancer. It is therefore likely that the ER
cofactors regulate estrogen binding to the estrogen receptors in
ER-positive endometrial cancer. Unfortunately, we were unable to
perform the sub-group analysis due to sample size limitation and
ER status information deficiency. As NCOA2 complex is formed by
5 genes (NCOA2, CARM1, CREBBP, PRMT1 and EP300) and the
coverage of common SNPs is low (50% in EP300 and 20% in
PRMT1) in the validation samples, we were not able to impute the
SNPs analyzed in the discovery study. Age and other risk factors
could potentially affect the results, but unfortunately, we could not
perform adjustment due to lack of information in the validation
study.
Population stratification is an important issue for genetic
association study. For the validation data of this study, all the
controls were from UK and had been carefully examined to
exclude any subjects of non-European ancestry [22]. All the cases
were from Australian and were also of European ancestry.
Therefore, the controls and cases are of the same ethnic ancestry.
Furthermore, this dataset has been used in a previously published
GWAS analysis [19] where PCA analysis showed that population
stratification is negligible. Consistently, the lGC value of the
genome-wide results is very small (1.04). Taken together, these
results suggested that the cases and the controls of the validation
dataset used in the current study were well matched genetically,
and the genetic association results of the current study should not
suffer the adverse impact of population stratification.
The current study provided a comprehensive analysis of
common genetic variants within the ER cofactor genes. First,
the large number of tag SNPs covered an average of 91% of
common variation (MAF.5%) within the 60 candidate genes
based on HapMap CEU data (NCBI36) (Table S1). The average
coverage decreased to 64% based on the 1000Genomes CEU data
(NCBI37), but the number of captured SNPs increased from 2585
to 5084. Imputation analysis was performed in the discovery and
validation samples to evaluate additional untyped SNPs and to
ensure that the same set of polymorphisms were analyzed in the
discovery and replication samples. With a total sample size of 1829
cases and 6700 controls, our study had an overall power of 85% at
a significance level of 0.05 to detect a causal allele with MAF over
0.1 and OR over 1.2 for endometrial cancer. However, we have
not found any evidence of association, despite the fact that the
association was evaluated by using individual SNP, genes or ER
cofactor complex based tests. Therefore, our study has demon-
strated that the common polymorphisms within these genes are
unlikely to play a significant role in overall endometrial cancer risk
in European population. However, we could not exclude the
Table 5. Sub-complex AML test for genetic association between the tag SNPs in the NCOA2 complex and endometrial cancer risk
in the validation analysis.
Sub-complex Gene #tagSNPs Gene- based Pglobal Complex-based Pglobal






Table 6. List of top five SNPs in the combined analysis in the NCOA2 and CREBBP gene respectively.





NCOA2 8 rs1531362 71315749 0.86(0.64,1.16)+ 0.89(0.76,1.05+ 0.89(0.77,1.02) 0.1
NCOA2 8 rs7818867 71286488 0.83(0.66,1.04) 0.94(0.82,1.08) 0.91(0.81,1.02) 0.11
NCOA2 8 rs17675762 71272507 0.86(0.68,1.07)+ 0.93(0.81,1.07) 0.91(0.81,1.02) 0.12
NCOA2 8 8-71359643 71359643 1.38(1.07,1.79) 1.02(0.86,1.21) 1.12(0.97,1.29) 0.12
NCOA2 8 rs11777228 71407844 1.36(0.97,1.89)+ 1.08(0.85,1.37) 1.16(0.96,1.42) 0.13
CREBBP 16 rs12599143 3790417 1.42(1.15,1.76) 0.99(0.86,1.15) 1.11(0.99,1.26) 0.079
CREBBP 16 rs130005 3768349 1.45(1.18,1.77) 0.97(0.83,1.13) 1.12(0.99,1.26) 0.083
CREBBP 16 rs129963 3736148 1.15(1.0,1.32)+ 1.04(0.95,1.13)+ 1.07(0.99,1.15) 0.085
CREBBP 16 rs2239317 3860741 1.37(1.12,1.68)+ 0.97(0.84,1.12) 1.09(0.97,1.23) 0.16
CREBBP 16 rs11644593 3811287 1.40(1.13,1.75) 0.97(0.83,1.13) 1.09(0.96,1.24) 0.18
+Real genotyped SNPs.
doi:10.1371/journal.pone.0042445.t006
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possibility that some SNPs could be associated with the
endometrial cancer survival. Further studies will be needed to
examine if common variants with weaker effect or rare variants
within these genes may play a role in influencing endometrial
cancer risk and survival.
Materials and Methods
Ethics Statement
This study was approved by the Institutional Review Boards in
Sweden and the National University of Singapore, the National
Health and Medical Research Council of Australia and the
Wellcome Trust Case Control Consortium UK. The patients in
this manuscript have given written informed consent to publica-
tion of their case details.
Study Population and DNA Extraction
Swedish population. Table 1 summarizes the origins, and
numbers of cases and controls used in this study. Subjects were
from two independent populations from Sweden and the stage 1
sample set of a recently published endometrial cancer GWAS [19].
Details of the Swedish population selection process for this study
have been published earlier [23,24]. In brief, 564 of all
endometrial cancer cases among women 50–74 years of age were
identified through the nation-wide cancer registries in Sweden
between 1994 and 1995. During that period, 1510 age-frequency
matched controls were randomly selected from the Swedish
Registry of Total Population. All cases and controls without any
previous malignancy were recruited into the study. Only women
with an intact uterus were considered as eligible controls. All
eligible subjects provided risk factor information including age,
reproductive history and body mass index (Table S2), which were
obtained via questionnaires.
In silico validation dataset. Our validation data were
drawn from the 1st stage of a GWAS of endometrial cancer,
detailed elsewhere [19]. In summary, the stage 1 cases were
primary endometrioid subtype endometrial cancer patients
reporting European ancestry from Australia (the Australian
National Endometrial Cancer Study (ANECS)) and the UK
(Studies of Epidemiology and Risk factors in Cancer Heredity
(SEARCH) Stage 1 controls were genotyped as part of the
Wellcome Trust Case Control Consortium (WTCCC) from
England, and included 2,694 controls from the 1958 Birth Cohort
(1958BC) (a population-based study in the United Kingdom of
individuals born in 1 week in 1958) and 2,496 controls identified
through the UK National Blood Service (NBS) [22]. Information
on epidemiological risk factors of case subjects from ANECS and
SEARCH were collected using respective questionnaires from the
two studies. However, this information was not available for the
present study.
For the discovery and validation samples, bio-specimen was
collected using written informed-consent procedures approved by
the respective institutional review boards.
Candidate Gene, Tagging SNP Selection and Genotyping
The details of ER cofactor genes and tag SNP selection have
been previously described [25]. In brief, gene selections were
based on the criteria that the gene should code for an ER cofactor
protein. We chose tag SNPs within the 60 candidate genes based
on the HapMap CEU data (Rel #22/phase II Apr07, on NCBI
B36 assembly, dbSNP b126). Using a pair-wise SNP tagging
approach with r2.0.8 in Haploview [26] (Version 4), 806 tagging
SNPs with MAF over 0.05 were selected within introns, exons and
the 5 Kb region flanking of each gene. Overall 790 tagSNPs across
60 genes were successfully designed and genotyped in all available
DNA samples from cases and controls with the Illumina Gold-
enGate Assay following the manufacturers’ instructions. Among
them, 105 SNPs were excluded on the basis of 81 SNPs having
a call rate less than 0.96, 6 SNPs failing a Hardy-Weinberg
Equilibrium test (P, (0.05/685)) and 18 SNPs having a MAF
,0.01. Finally, 685 tagSNPs were included in the statistical
analysis. Genotyping was duplicated in 2% of samples and there
was concordance of .99% between duplicated samples, suggest-
ing high genotyping accuracy.
For the validation analysis, the SNPs on the gene NCOA2,
CREBBP, PRMT1, EP300 and CARM1 were drawn from the
610 K panel based on the physical position of 5 kb flank of specific
gene regions. The details of genotyping have been described
previously [19]. Briefly, cases were genotyped with Illumina
Infinium 610 K array and controls were genotyped using an
Illumina Infinium 1.2 M array (Table 1). The following criteria
were used for SNPs filtering: call rate $95% if MAF $5% (or call
rate $99% if MAF ,5%), HWE P.10212 (cases) (or HWE
P.1027 if no discrepancy with the control groups) and P,1026
(controls). The duplicate concordance was over 99.9%. Cases and
controls were restricted to the following criteria: the sex of all
samples was confirmed to be female; the identity-by-descent
analysis based on identity-by-state was conducted to detect first-
degree cryptic relationships; the principle components analysis
(PCA) was utilized to remove non-European ancestry and all
samples with a low or high heterozygosity (,0.65 or.0.68) or call
rate,97% were excluded. A total of 1265 cases and 5190 controls
were used for analysis.
Statistical Analysis
To assess the risk association between SNPs and endometrial
cancer risk, per-allele odds ratio (ORs) and 95% confidence
intervals were estimated using a logistic regression in both Swedish
and validation GWAS genotyping data. The Cochran–Armitage
trend test was used to calculate P values. As the controls were
younger than cases in the Swedish study, age at diagnosis/
enrolment (as a continuous variable) was included for adjustment.
We used a Bonferroni correction to adjust for multiple testing (685
tests of association), although this is conservative as not all of the
tests are independent. As the information on age was absent from
provided GWAS data, we performed an un-adjusted analysis for
the validation set.
Overall evidence of association between the genetic variants in
the ER cofactor complex and endometrial cancer risk was
evaluated using the Admixture Maximum Likelihood (AML)
method, which is described in detail in Tyrer et al [27] and in our
previous study [18]. Briefly, the software for the AML test assesses
the experiment-wise significance by examining the empirical
distribution of single marker test statistics based on a ‘‘pseudo-
likelihood ratio’’ test, comparing the ratio of values of the
optimized likelihoods under the null and alternative hypotheses
for the observed data, with the corresponding values obtained
from data sets with case-control status permuted randomly. The
method is based upon fitting a mixture model to the distribution of
the test statistics, and has two components, one representing SNPs
which are independent of the case-control status, the other
representing SNPs associated with case-control status. In order to
determine whether there exists a cumulative effect from multiple
variants, the Cochran-Armitage test statistics for the associated
SNPs are assumed to all have the same non-centrality parameter
value (chi-squared). The common effect size of the associated
SNPs within the complex is also estimated through the non-
centrality parameter. We performed the AML-based global test of
SNPs in ER Cofactors and Endometrial Cancer Risk
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association for the 5 ER cofactor complexes, 3 sub-complexes and
60 ER cofactor genes specific analysis in Swedish analysis, as well
as for NCOA2 sub-complex in the validation data analysis. This
test assesses the experiment-wise significance by examining the
empirical distribution of single marker test statistics, in order to
determine whether there exists a cumulative effect from multiple
variants.
For the imputation analysis of NCOA2 (Chr8: 71181–
71484 kbp) and CREBBP (Chr16: 3720–3875 kbp), we imputed
the two regions in the two datasets: 2074 Swedish samples and
6455 validation samples, by using their genotyped SNPs whose
genotypes all passed the QC thresholds (call rate .90%, MAF
.1%, HWE P.1026 in controls). Imputation was performed by
using the data from 1000 Genomes [28] as reference panel 0 and
the data from HapMap III [29] as reference panel 1 (CEU data) in
a single imputation analysis, as recommended by the authors of
Impute2. Imputed genotypes with probability less than 90% were
excluded; and SNPs with impute info less than 80%, MAF less
than 1%, HWE P,0.0001 in controls and missing rate greater
than 10% of genotypes were dropped from further analysis.
Association testing was performed in PLINK [29] by using
Cochran-Armitage trend test to analyze the genotype–phenotype
association in both studies. In the meta-analysis, the Cochran–
Mantel–Haenszel test was applied to test genotype-phenotype
association in the combined samples by treating the two individual
samples as independent studies. The Breslow-Day test and the Q
test were performed to evaluate the significance of heterogeneity
among individual studies.
SNP association analyses were performed using STATA version
8.0 (StataCorp, College station, TX, USA). Linkage disequilibri-
um (LD) calculation was performed in Haploview version 4.1 [26].
The AML analysis was performed using a software obtained from
the authors of the method [27]. The software Quanto version
1.2.3 was used for power estimation [30]. The software IMPUTE
version 2 [31,32] was used for imputing genotype data of untyped
SNPs.
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